You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

IMMPHENTIV Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Immphentiv, and when can generic versions of Immphentiv launch?

Immphentiv is a drug marketed by Hikma and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in IMMPHENTIV is phenylephrine hydrochloride. There are twenty-one drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the phenylephrine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Immphentiv

A generic version of IMMPHENTIV was approved as phenylephrine hydrochloride by HIKMA on December 20th, 2012.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for IMMPHENTIV?
  • What are the global sales for IMMPHENTIV?
  • What is Average Wholesale Price for IMMPHENTIV?
Summary for IMMPHENTIV
Drug patent expirations by year for IMMPHENTIV
Drug Prices for IMMPHENTIV

See drug prices for IMMPHENTIV

Pharmacology for IMMPHENTIV

US Patents and Regulatory Information for IMMPHENTIV

IMMPHENTIV is protected by two US patents.

Patents protecting IMMPHENTIV

Phenylephrine hydrochloride ready-to-use solution
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma IMMPHENTIV phenylephrine hydrochloride SOLUTION;INTRAVENOUS 203826-004 Mar 9, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hikma IMMPHENTIV phenylephrine hydrochloride SOLUTION;INTRAVENOUS 203826-005 Mar 9, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hikma IMMPHENTIV phenylephrine hydrochloride SOLUTION;INTRAVENOUS 203826-004 Mar 9, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hikma IMMPHENTIV phenylephrine hydrochloride SOLUTION;INTRAVENOUS 203826-005 Mar 9, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.